Alzheimer's & Dementia: The Journal of the Alzheimer's Association
Volume 5, Issue 3 , Pages 271-275, May 2009

Maximizing the Alzheimer's Disease Neuroimaging Initiative II

  • Maria C. Carrillo

      Affiliations

    • Alzheimer's Association, Chicago, IL, USA
    • Corresponding Author InformationCorresponding author. Tel.: 312-335-5722.
    • ,
  • Charles A. Sanders

      Affiliations

    • Foundation for the National Institutes of Health, Bethesda, MD, USA
    • ,
  • Russell G. Katz

      Affiliations

    • United States Food and Drug Administration, Washington, DC, USA

published online 13 April 2009.

Abstract 

The Alzheimer's Disease Neuroimaging Initiative is the largest public-private partnership on brain research underway at the National Institutes of Health. This 6-year study tracks cognitive and brain changes in normal subjects, those with mild cognitive impairment, and individuals with Alzheimer's disease. It was designed to provide better tools for performing effective clinical trials, and is slated to run until 2010. While data are being generated and analyzed, researchers involved in the study are developing an extension, i.e., the Alzheimer's Disease Neuroimaging Initiative II. The Foundation for the National Institutes of Health and the Alzheimer's Association convened a meeting to review the progress, evaluate future directions, and obtain the United States Food and Drug Administration's perspective on how the Alzheimer's Disease Neuroimaging Initiative could affect the drug-approval process.

Keywords: Alzheimer's disease, Biomarkers, Neuroimaging, Early defection, Longitudinal study, Natural history study, Mild cognitive impairment

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 30.00 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

 The views stated here represent those of R.G.K., and do not represent an official statement of the United States Food and Drug Administration.

PII: S1552-5260(09)00057-0

doi:10.1016/j.jalz.2009.02.005

Alzheimer's & Dementia: The Journal of the Alzheimer's Association
Volume 5, Issue 3 , Pages 271-275, May 2009

Article Tools